GDNF-containing DNA nanoparticle therapy (University of Kentucky/Copernicus Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameGDNF-containing DNA nanoparticle therapy (University of Kentucky/Copernicus Therapeutics)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionGlial cell line-derived neurotrophic factors stimulants
TargetsGlial cell line-derived neurotrophic factors
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Kentucky
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCopernicus TherapeuticsUniversity Of Kentucky
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A